Table 3 Polysensitization
Characteristic | No polysensitization | Polysensitization | p | ||||||
|---|---|---|---|---|---|---|---|---|---|
Mean/n/% | SD | Median | IQR | Mean/n/% | SD | Median | IQR | ||
General | |||||||||
n (male/female) | 124 (50/74) | 37 (15/22) | 0.981 | ||||||
Age (years) | 53.36 | 10.94 | 52.00 | 17.00 | 51.62 | 12.68 | 52.00 | 18.00 | 0.546 |
Weight (kg) | 77.64 | 17.23 | 75.00 | 24.50 | 80.27 | 17.88 | 80.00 | 27.00 | 0.385 |
Total IgE (IU/ml) | 328.83 | 294.71 | 204.50 | 377.00 | 418.84 | 358.10 | 304.00 | 444.00 | 0.178 |
Omalizumab dose (mg/month) | 483.87 | 247.80 | 450.00 | 300.00 | 419.59 | 240.74 | 300.00 | 300.00 | 0.109 |
Baseline | |||||||||
FeNO (ppb) | 51.26 | 50.23 | 38.00 | 48.00 | 50.14 | 42.93 | 38.00 | 59.00 | 0.891 |
ACT (points) | 12.19 | 3.68 | 12.00 | 5.50 | 13.73 | 4.23 | 14.00 | 7.00 | 0.065 |
FEV1 (%pred) | 63.61 | 18.65 | 66.50 | 24.00 | 63.49 | 16.83 | 61.00 | 15.00 | 0.576 |
Severe exacerbations (n/year) | 2.98 | 4.89 | 2.00 | 3.00 | 2.08 | 3.14 | 1.00 | 1.00 | 0.080 |
Systemic corticosteroids (n/%) | 97 (78.2%) | 22 (59.5%) | 0.023 | ||||||
Prednisone (mg/day) | 13.29 | 14.86 | 7.00 | 15.00 | 15.82 | 20.71 | 10.00 | 15.00 | 0.239 |
Final | |||||||||
FeNO (ppb) | 37.01 | 37.66 | 24.00 | 26.00 | 28.78 | 32.50 | 20.00 | 32.00 | 0.114 |
ACT (points) | 18.63 | 4.81 | 20.00 | 7.00 | 17.53 | 4.48 | 17.00 | 7.50 | 0.159 |
FEV1 (%pred) | 72.43 | 23.14 | 76.00 | 30.00 | 71.31 | 18.71 | 68.50 | 22.50 | 0.560 |
Severe exacerbations (n/year) | 0.85 | 2.46 | 0.00 | 1.00 | 1.25 | 3.01 | 0.00 | 1.00 | 0.581 |
Systemic corticosteroids (n/%) | 54 (43.5%) | 14 (20.6%) | 0.537 | ||||||
Prednisone (mg/day) | 7.94 | 8.95 | 5.00 | 8.00 | 13.43 | 17.87 | 5.00 | 5.00 | 0.308 |